Novavax shares plunge 12% amid vaccine sector selloff, Moderna down 10%, Pfizer steady.

Novavax stock dropped 12% due to heavy selling pressure on vaccine makers, with Moderna also falling 10% while Pfizer remained stable. Novavax depends on Sanofi to commercialize its COVID vaccine, making its revenue reliant on Sanofi's rollout and milestone payments. Citi maintains a Sell rating on Novavax despite raising its price target, reflecting uncertainty about the timing of revenue from partner milestones. Investors should watch Sanofi's vaccine rollout progress as it will determine Novavax's future royalty income and stock performance.

Novavax shares fell 12.25% to USD 11.25 on Pluang as of Oct 17, 2026 00:02 WIB, matching the article's noted drop. Moderna also declined 9.18% to USD 214.79, while Pfizer edged up 0.46% to USD 29.57. Sanofi, key to Novavax's revenue, was nearly flat at USD 40.32, showing little immediate market reaction to vaccine rollout news.